左心室辅助装置中的直接口服抗凝药:现状与展望
本文综述直接口服抗凝药(DOAC)在左心室辅助装置(LVAD)患者中的应用现状,重点为HeartMate 3。阿哌沙班是研究最多的DOAC,在严格选择患者中可能作为维生素K拮抗剂(VKA)的替代,降低出血风险而不牺牲抗栓保护;但证据受样本量小、随访短和人群选择性限制。
要点
- 阿哌沙班是HeartMate 3背景下研究最多的DOAC,可能作为VKA的替代。
- 现有证据受样本量小、随访时间短和患者选择性强限制。
- 最佳剂量、启动时机、监测及心脏移植等待者等亚组安全性尚不明确。
核心结论
- 阿哌沙班在严格选择的LVAD患者中日益被视为有前景的VKA替代,可能重塑该人群抗凝实践,但仍需更多数据明确其地位。
研究设计与样本
- 综述,检索范围与纳入研究数量原文未报告。
主要发现
- 尽管HeartMate 3技术进步,血液相容性相关不良事件(HRAEs)尤其出血仍常见,因患者-装置相互作用复杂且需抗凝。
- DOAC因药代动力学可预测、固定剂量及在其他人群出血风险较低而受关注。
- 阿哌沙班在HeartMate 3中研究最广,可能在严格选择患者中降低出血风险而不损害血栓保护。
- 现有证据受样本量小、随访短和选择人群限制。
临床怎么用
- 阿哌沙班可考虑用于严格选择的HeartMate 3患者作为VKA替代,但需权衡出血与血栓风险。
- 最佳剂量、启动时机和监测策略尚无定论,需个体化决策。
局限性
- 证据受样本量小、随访时间短和患者选择性限制。
- 最佳剂量、启动时机、水平监测及脆弱亚组(尤其等待心脏移植者)安全性存在重要空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite significant advances in left ventricular assist device (LVAD) technology, particularly with the HeartMate 3, hemocompatibility-related adverse events (HRAEs), especially bleeding, remain common due to complex patient-device interactions and the need for anticoagulation. This has prompted interest in exploring new and less aggressive antithrombotic strategies. Direct oral anticoagulants (DOACs) have gained attention for their predictable pharmacokinetics, fixed dosing, and lower bleeding risk in other populations. Among them, apixaban has emerged as the most extensively studied DOAC in the HeartMate 3 setting, standing out as a promising alternative to VKAs in carefully selected patients, with the potential to lower bleeding risk without compromising thrombotic protection. However, available evidence remains limited by small sample sizes, short follow-up, and selected patient populations. Important gaps persist regarding optimal dosing, timing of initiation, level monitoring, and safety in vulnerable subgroups, particularly patients awaiting heart transplantation. This review synthesizes the current evidence on DOAC use in HeartMate 3-supported patients, provides practical guidance for real-world decision-making, and highlights areas where further research is needed. Although more data are required to define its role, apixaban is increasingly positioned as a promising VKA alternative in LVAD-patients and could ultimately reshape anticoagulation practice in this population.
引用
- Blazquez-Arroyo L, Gallone G, Baldetti L, et al. Direct oral anticoagulants in left ventricular assist devices: Where are we now? J Heart Lung Transplant. 2025. PMID: 40947080. doi:10.1016/j.healun.2025.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。